NCT05535023View on ClinicalTrials.gov

Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 24, 2022

Primary Completion Date

July 25, 2023

Study Completion Date

July 25, 2023

Conditions
Squamous Cell CarcinomaOropharynx CancerHead and Neck Cancer
Interventions
DRUG

SAR444245

Given by vein (IV)

DRUG

Cemiplimab

Given by vein (IV)

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT05535023 - Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter